Marker Therapeutics (MRKR) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Technology overview and differentiation

• MAR-T platform is a first-in-class, natural T-cell therapy that does not require genetic modification and targets multiple tumor antigens.

• Demonstrates a favorable safety profile with no ICANS, HLH, or severe CRS observed in clinical studies.

• Manufacturing process is straightforward, with a current vein-to-vein time of 22 days, aiming to reduce to 17 days.

• Technology is licensed from Baylor College of Medicine, with global intellectual property rights.

Clinical data and efficacy

• MT-601 shows a 66% overall response rate in non-Hodgkin lymphoma and 78% in Hodgkin lymphoma, including heavily pretreated patients.

• Complete response rate in non-Hodgkin lymphoma is 50%, with durable responses observed beyond one year.

• Responses are seen even at lower dose levels, with dose escalation up to 400 million cells well tolerated.

• No dose-limiting toxicities or long-term adverse effects reported; only mild, manageable CRS.

Strategic focus and market opportunity

• Priority is to advance MT-601 as a single-arm pivotal study for LBCL patients who failed CAR T-cell therapy.

• LBCL post-CAR T-cell market could exceed $3 billion by 2030.

• Expansion plans include solid tumors (pancreatic cancer) and an off-the-shelf AML program.

• Government grants exceeding $30 million support clinical development and de-risk new programs.